ISSN / EISSN : 0085-2538 / 1523-1755
Published by: Elsevier BV (10.1016)
Total articles ≅ 22,555
Latest articles in this journal
Kidney International, Volume 100; doi:10.1016/j.kint.2021.06.005
Anecdotal reports linking minimal change disease (MCD) to vaccinations possibly due to immune dysregulation,1Clajus C. Spiegel J. Brocker V. et al.Minimal change nephrotic syndrome in an 82 year old patient following a tetanus-diphtheria-poliomyelitis-vaccination.BMC Nephrol. 2009; 10: 21Crossref PubMed Scopus (6) Google Scholar including influenza vaccine,2Kielstein J.T. Termuhlen L. Sohn J. Minimal change nephrotic syndrome in a 65-year-old patient following influenza vaccination.Clin Nephrol. 2000; 54: 246-248PubMed Google Scholar pneumococcal,3Kikuchi Y. Imakiire T. Hyodo T. et al.Minimal change nephrotic syndrome, lymphadenopathy and hyperimmunoglobulinemia after immunization with a pneumococcal vaccine.Clin Nephrol. 2002; 58: 68-72Crossref PubMed Google Scholar meningococcal C vaccines,4Abeyagunawardena A. Goldblatt D. Andrews N. Trompeter R. Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome.Lancet. 2003; 362: 449-450Abstract Full Text Full Text PDF PubMed Scopus (38) Google Scholar and BNT162b2 coronavirus disease 2019 (COVID-19) vaccine (Pfizer-BioNTech)5Lebedev L, Sapojnikov M, Wechsler A, et al. Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine [e-pub ahead of print]. Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2021.03.010. Accessed June 20, 2021.Google Scholar,6D’Agati VD, Kudose S, Bomback AS, et al. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine [e-pub ahead of print]. Kidney Int. https://doi.org/10.1016/j.kint.2021.04.035.Google Scholar have been published. We report 2 cases of biopsy-proven MCD relapsing within 2 days of receiving an AstraZeneca COVID-19 vaccine.
Kidney International, Volume 100, pp 474-476; doi:10.1016/j.kint.2021.05.016
The mRNA-1273 (Moderna) vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the current coronavirus disease 2019 (COVID-19) pandemic. In a randomized placebo-controlled phase 3 trial, the mRNA-1273 (Moderna) vaccine showed high efficacy at preventing COVID-19. Aside from transient local and systemic reactions, no safety concerns were identified.1Baden L.R. El Sahly H.M. Essink B. et al.Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.N Engl J Med. 2021; 384: 403-416Crossref PubMed Scopus (490) Google Scholar
Kidney International, Volume 100, pp 463-464; doi:10.1016/j.kint.2021.05.007
The immunologic response following several varieties of vaccination has been described as a potential trigger for the development of both de novo as well as recurrent minimal change (MCD) disease (1Gutiérrez S. Dotto B. Petiti J.P. et al.Minimal change disease following influenza vaccination and acute renal failure: just a coincidence?.Nefrologia. 2012 May 14; 32: 414-415PubMed Google Scholar). There have been emerging cases, including that described by Kervella et al. of MCD shortly after vaccination with the BNT162b2 vaccine (Pfizer-BioNTech) (2Lebedev L. Sapojnikov M. Wechsler et al.Minimal change disease following the Pfizer-BioNTech COVID-19 Vaccine.American Journal of Kidney Diseases. 2021 Apr 8; (S0272-6386(21)00509-6)Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar, 3Kervella D. Jacquemont L. Chapelet-Debout A. et al.Minimal change disease relapse following SARS-CoV2 mRNA vaccine.Kidney Int. 2021 May 5; (S0085-2538(21)00478-6)Abstract Full Text Full Text PDF PubMed Google Scholar). We report to the best of the author’s knowledge the first case of minimal change disease presenting as nephrotic syndrome following the Moderna mRNA-1273 SARS-CoV-2 vaccine.
Kidney International, Volume 100; doi:10.1016/s0085-2538(21)00517-2
Kidney International; doi:10.1016/j.kint.2021.05.040
Lineage tracing was originally developed by developmental biologists to identify all progeny of a single cell during morphogenesis. More recently this approach has been applied to other fields, including organ homeostasis and recovery from injury. Modern lineage tracing techniques typically rely on reporter gene expression induced by cell-specific DNA recombination. There have been important scientific advances in the last ten years that have impacted lineage tracing approaches, including intersectional genetics, optical clearing techniques and the use of sequencing-based genomic lineage tracing. The latter combines CRISPR-Cas9 based genetic scarring with single cell RNA-sequencing which in theory could allow comprehensive reconstruction of a lineage tree for an entire organism. In this review, we summarize recent advances in lineage tracing technologies and outline potential applications for kidney research.
Kidney International, Volume 100, pp 32-34; doi:10.1016/j.kint.2021.03.030
Kidney International, Volume 100, pp 240-241; doi:10.1016/j.kint.2021.04.018
Kidney International, Volume 100, pp 238-238; doi:10.1016/j.kint.2021.04.024
Kidney International, Volume 100, pp 14-16; doi:10.1016/j.kint.2021.04.030
Hanudel et al. investigated the effects of hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) on iron metabolism in a chronic kidney disease (CKD) mouse model and showed that vadadustat, an HIF-PHI, exerted beneficial effects on anemia and iron disorders independently of erythroferrone. Vadadustat also inhibited the progression of CKD and the CKD-associated increase of plasma fibroblast growth factor 23 in CKD mice. This study provides new insights into the action of HIF-PIHs in CKD.
Kidney International; doi:10.1016/j.kint.2021.06.036
The most frequently used immunosuppressive treatment in kidney transplant recipients is the combination therapy of a calcineurin inhibitor and mycophenolate mofetil (MMF), with or without corticosteroids. Cyclosporin and tacrolimus are the two calcineurin inhibitors registered for this indication. Also in the treatment of glomerular diseases calcineurin inhibitors and mycophenolic acid are being used on a worldwide scale, either alone or as combined treatment. In January 2021 the U.S. Food and Drug Administration (FDA) has approved voclosporin, a novel calcineurin inhibitor for the treatment of adult patients with active lupus nephritis. There is a clinically relevant drug-drug interaction between cyclosporin and mycophenolate. As a result of cyclosporin-induced inhibition of the enterohepatic recirculation of mycophenolate, the mycophenolic acid-AUC is significantly lower (40%) in case of cyclosporin co-administration as compared to cotreatment with either tacrolimus or voclosporin (or no CNI co-treatment). The aim of this mini review is to summarize this potential drug-drug interaction and explain how cyclosporin affects the pharmacokinetics of mycophenolate. The optimal dose of MMF is likely to depend on the calcineurin inhibitor with which it is co-administered. Furthermore clinical implications are discussed, including the potential emergence of mycophenolic acid (MPA)-related side effects after discontinuation of cyclosporin co-treatment.